Combining Radiation- with Immunotherapy in Prostate Cancer: Influence of Radiation on T Cells

Int J Mol Sci. 2022 Jul 18;23(14):7922. doi: 10.3390/ijms23147922.

Abstract

Radiation of tumor cells can lead to the selection and outgrowth of tumor escape variants. As radioresistant tumor cells are still sensitive to retargeting of T cells, it appears promising to combine radio- with immunotherapy keeping in mind that the radiation of tumors favors the local conditions for immunotherapy. However, radiation of solid tumors will not only hit the tumor cells but also the infiltrated immune cells. Therefore, we wanted to learn how radiation influences the functionality of T cells with respect to retargeting to tumor cells via a conventional bispecific T cell engager (BiTE) and our previously described modular BiTE format UNImAb. T cells were irradiated between 2 and 50 Gy. Low dose radiation of T cells up to about 20 Gy caused an increased release of the cytokines IL-2, TNF and interferon-γ and an improved capability to kill target cells. Although radiation with 50 Gy strongly reduced the function of the T cells, it did not completely abrogate the functionality of the T cells.

Keywords: bispecific T cell engager; immunotherapy; prostate cancer; prostate stem cell antigen; radiation.

MeSH terms

  • Antibodies, Bispecific*
  • Humans
  • Immunologic Factors
  • Immunotherapy / methods
  • Male
  • Prostatic Neoplasms* / drug therapy
  • Prostatic Neoplasms* / radiotherapy
  • T-Lymphocytes

Substances

  • Antibodies, Bispecific
  • Immunologic Factors